Are combination therapies more effective for the treatment of relapsed refractory CLL?
Why the rapid development of new drugs poses new challenges
An overview of the European Reference Networks and EuroBloodNet
Joan Lluis Vives-Corrons et al.
Integrating cellular therapies into clinical practice
Day 1 Highlights from the chair of BOPA 2017